Skip to main content
. 2021 Mar 10;11:5562. doi: 10.1038/s41598-021-85152-2

Figure 3.

Figure 3

Disease activity and galectin-9 (Gal-9) levels in T cell subsets and plasma at baseline in different groups among 77 rheumatoid arthritis (RA) patients. Patients were divided into a mild group (Mi, n = 16), moderate group (Mo, n = 44) and severe group (Se, n = 17). Results were also compared with those of controls. (A) Groups according to disease activity score 28 (DAS28). (B) Gal-9 expression in CD4 + and regulatory (Treg) T cell subsets. (C) Gal-9 expression in plasma in different RA groups and controls (n = 58). (DF) Differences in (D) DAS28, (E) Gal-9 expression in CD3 + T cell subsets, and (F) Gal-9 expression in plasma between groups with clinical disease activity index (CDAI) ≤ 10 (n = 7) or > 10 (n = 70). Comparisons between two groups were assessed using an independent-samples t-test, while comparisons among three groups were assessed using one-way ANOVA. *P < 0.05, **P < 0.01.